Dr. Munavalli and Vic Ross, M.D., Scripps Clinic, San Diego, Calif., were co-investigators in the initial feasibility study. Eligible patients could have up to two warts treated and needed to have a third wart that could be left untreated as a control. They were seen for follow-up after seven, 30 and 60 days.
Reduction in wart size was often seen at the 30-day visit, and tissue recovery at sites of cleared warts was rapid and complete. The treatment was associated with immediate pinpoint bleeding and swelling and sometimes hemorrhagic blisters and crust formation.
“These local reactions were all self-limited and similar to what we see with other destructive technologies,” says Dr. Munavalli.
“However, because the treatment zone with other options, such as cryotherapy, is not very controllable, they can cause damage to surrounding skin. In contrast, the effect of NPS is very specific to the area covered by the treatment tip, and in this study, we had positive patient reports of a minimal pain recovery period.”
The NPS treatment was associated with some residual erythema that tends to fade over time, as well as a low incidence of hyperpigmentation, which may be reduced through future re nement of the treatment parameters.
“Overall, patient satisfaction has been very high, which is not surprising considering that our cohort included patients who were probably frustrated after failing other therapies,” says Dr. Munavalli.
Drs. Munavalli and Ross are investigators and members of the scientific advisory board for Pulse Biosciences.